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INTRODUCTION
Theophylline is used for the treatment of asthma
and chronic obstructive pulmonary disease. The
effective serum level of theophylline for asthma is
over 5 µg/mL (1, 2). The toxic serum level is over 20
µg/mL, and may induce headache, nausea, vomiting,
palpitations, insomnia, diarrhea, or rhabdomyolysis
(3, 4). Furthermore, cardiac arrhythmias or seizures,
which are sometimes fatal, may occur with more
than 40 µg/mL (5, 6). Therefore, these adverse
effects are generally induced by the increase in
serum theophylline, which is often caused by an
overdose of theophylline or some theophylline
metabolism-inhibiting drugs such as macrolides,
quinolones, cimetidine and so on (pharmacokinetic
drug interaction) (7-9).
Rhabdomyolysis, the colliquation and necrosis
of skeletal muscle, is one of the serious adverse
effects of theophylline (10, 11). The symptoms
include adynamia, pain and swelling of extremital
muscles, numbness, myoglobinuria and acute renal
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failure (12, 13). A high level of serum creatine
kinase (CK) may serve as an index in diagnosing
or predicting rhabdomyolysis (14, 15).
CK, a component of muscle cells, is present at
high levels in serum in these conditions. This in-
crease in CK results from damage to skeletal muscle
or cardiac tissue, including acute myocardial infarc-
tion, muscular dystrophy, and polymyositis. It is
also involved in trauma, seizures, hypothyroidism,
rhabdomyolysis. The overdose of certain drugs in-
cluding theophylline may also induce rhabdomyolysis
(16, 17).
Theophylline is often administered together with
drugs that potentially elevate the serum CK level
(CK-elevating drugs) such as β-agonists, steroids,
and antihyperlipidemics (18). However, the effects
of this combined treatment, which may increase the
serum CK level and possibly induce rhabdomyolysis,
have not been reported. We retrospectively investi-
gated the effects of this combined treatment on the
serum CK level in 391 asthmatic outpatients.
PATIENTS AND METHODS
PATIENTS
The present study was performed on a total of 391
outpatients (female : 230, male : 161) with asthma
ranging in age from 18 to 77 years (mean±SE : 55
±1). They were examined at the Asthmatic Con-
sultation of the Third Department of Internal
Medicine, University Hospital, The University of
Tokushima School of Medicine, from January 1995 to
September 1997. We examined the number and kind
of prescribed drugs and the CK and theophylline
serum levels in these patients, retrospectively from
their medical records.
The 391 patients were first divided into theophylline-
treated (313 patients) and non-theophylline-treated
(78 patients) groups. Of the theophylline-treated
patients, 124 had been treated with CK-elevating drugs
(theophylline-treated and CK-elevating drug-treated
group), and 189 had not (theophylline-treated
and non-CK-elevating drug-treated group). Of the
non-theophylline-treated patients, 15 had been treated
with CK-elevating drugs (non-theophylline-treated
and CK-elevating drug-treated group), and 63 had
not (non-theophylline-treated and non-CK-elevating
drug-treated group) (Table 1).
Next, in the theophylline-treated and CK-elevating
drug-treated group (124 patients), we examined the
serum theophylline levels of 77 patients and divided
them into two groups, namely, the CK-elevating
drug-treated and theophylline-elevating drug-treated
group (23 patients) and the CK-elevating drug-treated
and non-theophylline-elevating drug-treated group
(54 patients). In the theophylline-treated and
non-CK-elevating drug-treated group (189 patients),
we examined the serum theophylline levels of 92
patients and similarly divided them into two groups,
namely, the non-CK-elevating drug-treated and
theophylline-elevating drug-treated group (19
patients) and the non-CK-elevating drug-treated
and non-theophylline-elevating drug-treated group
(73 patients) (Table 2). Theophylline-elevating drugs
were defined as drugs that elevate the serum
Table 1 . Characteristics of asthmatic outpatients
Theophylline-treated
CK-elevating drug
Non-theophylline-treated
CK-elevating drug Total
(+) (-) Total (+) (-) Total
Number of outpatients
female
male
total
Age (Mean±SE)
range
CK-elevating drugs
β-agonist
steroid
antihyperlipidemic
others
total
80
44
124
55±1
(22-77)
80
54
25
20
179
98
91
189
54±1
(18-76)
178
135
313
55±1
(18-77)
12
3
15
64±3
(49-73)
4
7
3
1
15
40
23
63
51±2
(22-73)
52
26
78
54±2
(22-73)
230
161
391
55±1
(18-77)
84
61
28
21
194
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theophylline level ; the elevation was probably due
to the inhibition of theophylline metabolism.
METHODS
The serum CK levels were measured by UV
spectral analysis using the autoanalyzer 736 (Hitachi,
Japan) for 391 patients. The serum theophylline
levels were measured with an enzyme-multiple
immunoassay technique using the analyzer 7150
(Hitachi, Japan) for 169 patients.
Statistics
ANOVA and Fisher’s PLSD test for multiple
comparisons were used to compare the serum levels
of CK or theophylline between two groups. Differ-
ences were considered significant at P<0.01.
RESULTS
Serum CK levels
Some 179 CK-elevating drugs were used (1.4
drugs/person on average) in the theophylline-treated
and CK-elevating drug-treated group. One drug was
used for each patient (1.0 drug/person on average)
in the non-theophylline-treated and CK-elevating
drug-treated group. β-agonists, steroids and anti-
hyperlipidemics were used as CK-elevating drugs
(Table 1).
The mean (±SE) serum CK level of the 313
theophylline-treated patients was 164±11 IU/L.
This was significantly higher (P<0.0001) than that
of the 78 non-theophylline-treated patients (102±7
IU/L).
As shown in Fig.1, the mean (±SE) serum CK
level of the theophylline-treated and CK-elevating
drug-treated group (124 patients) was 225±25 IU/L,
significantly higher than the value for any other
group (P<0.01). The mean serum CK level of the
theophylline-treated and non-CK-elevating drug-treated
group (189 patients) was 124±6 IU/L, that of the
non-theophylline-treated and CK-elevating drug-treated
group (15 patients) was 102±14 IU/L, and that of
the non-theophylline-treated and non-CK-elevating
Table 2 . Characteristics of theophylline-treated asthmatic outpatients whose serum theophylline levels were examined
CK-elevating drug-treated
Theophylline-elevating drug
Non-CK-elevating drug-treated
Theophylline-elevating drug Total
(+) (-) Total (+) (-) Total
Number of outpatients
female
male
total
Age (Mean±SE)
range
Theophylline-elevating
drugs
macrolide
allopurinol
others
total
12
11
23
55±1
(39-70)
12
13
4
29
37
17
54
54±1
(30-74)
49
28
77
54±1
(30-74)
11
8
19
62±3
(41-76)
14
10
11
35
35
38
73
55±2
(20-75)
46
46
92
56±1
(20-76)
95
74
169
55±1
(20-76)
26
23
15
64
Fig. 1. Serum CK levels (mean±SE) of asthmatic outpatients.
Patients were divided into four groups, namely Th(+)・CK(+)
(theophylline-treated and CK-elevating drug-treated group),
Th(+)・CK(-) (theophylline-treated and non-CK-elevating
drug-treated group), Th(-)・CK(+) (non-theophylline-treated
and CK-elevating drug-treated group), and Th(-)・CK(-)
(non-theophylline-treated and non-CK-elevating drug-treated
group).
*P<0.01 compared with Th(+)・CK(-), Th(-)・CK(+) and Th(-)・
CK(-).
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drug-treated group (63 patients) was 102±8 IU/L.
No significant difference was obtained between any
two of these three groups.
Serum theophylline levels
As shown in Table 3, the mean (±SE) serum
theophylline level of the CK-elevating drug-treated
and theophylline-elevating drug-treated group (23
patients) was 11.2±1.1µg/ml, that of the CK-elevating
drug-treated and non-theophylline-elevating drug-treated
group (54 patients) was 9.1±0.5 µg/ml, that of the
non-CK-elevating drug-treated and theophylline-elevating
drug-treated group (19 patients) was 8.7±1.3 µg/ml,
and that of the non-CK-elevating drug-treated and
non-theophylline-elevating drug-treated group (73
patients) was 8.7±0.5µg/ml. No significant difference
was obtained between any two groups.
DISCUSSION
In the present study, the relationships of the
number and kind of drugs used in combination
with theophylline and the serum levels of CK and
theophylline were investigated in outpatients with
asthma. Theophylline was used in combination with
many kinds of drugs, such as β-agonists, steroids,
antihyperlipidemics, macrolides, and allopurinol
(Table 1, 2). These drugs potentially affect the
serum level of CK or theophylline (7-9). Although
investigators have reported that the serum CK level
elevated as a result of theophylline administration
(17, 19, 20), the effects of the combined therapy of
theophylline and CK-elevating drugs have not been
reported. In the present study, a higher level of
serum CK was observed only in the patients treated
with both theophylline and the CK-elevating drugs,
without an increase in the serum theophylline level
(Fig. 1, Table 3). However, the elevated CK level
(225 IU/L ; normal range : under 180 IU/L) was
not as high as that associated with rhabdomyolisis
(3-fold the normal limit) (21).
First, we compared the serum CK level of the
theophylline-treated patients (164 IU/L) with that
of the non-theophylline-treated patients (102 IU/L).
This significant difference was suggested to be due
to the CK-elevating effect of theophylline. However,
this effect could have been caused by the combi-
nation of CK-elevating drugs with theophylline.
Therefore, we examined the effects of theophylline
in combination with and without the CK-elevating
drugs on the serum CK level. The CK levels might
be elevated by either theophylline or the CK-elevating
drugs, but were not increased in the present study
probably because the doses were not high enough.
As shown in Fig.1, the combined treatment of
theophylline and the CK-elevating drug produced
about 100 IU/L higher levels than any other treat-
ment. While 1.0 CK-elevating drug per person was
used in the non-theophylline-treated and CK-elevating
drug-treated group, 1.4 CK-elevating drugs per person
were used in the combined treatment group. This
could have caused the higher serum CK level. For
the combined treatment, however, the serum CK level
of the patients treated with just one CK-elevating
drug was almost the same as that of the patients
treated with two or more CK-elevating drugs (data
not shown).
Neither the single use of theophyline nor that of the
CK-elevating drug significantly affected the CK level,
compared with the value for the non-theophylline-treated
and non-CK-elevating drug-treated group. The com-
bined treatment of theophylline and the CK-elevating
drug increased the serum CK level, probably via a
synergistic effect (Fig.1). However, this effect might
be due to the higher level of serum theophylline in
the combined treatment group than in any other
group.
Therefore, we examined the serum theophylline
levels in 169 out of the theophylline-treated patients
(Table 3). The mean serum theophylline level of
the 23 patients treated with both the CK-elevating
drug and theophylline-elevating drug appeared to
be higher than that of any other group, however,
Table 3. Serum theophylline level of asthmatic outpatients treated with theophylline
CK-elevating drug-teated
Theophylline-elevating drug
Non-CK-elevating drug-treated
Theophylline-elevating drug
(+) (-) Total (+) (-) Total
Serum theophylline level
(µg/mL) (Mean±SE) 11.2±1.1 9.1±0.5 9.7±0.5 8.7±1.3 8.7±0.5 8.7±0.5
Not significantly different between any two groups.
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no significant difference was obtained. Accordingly,
the increase in serum CK level with the combined
treatment of theophylline and the CK-elevating drug
is independent of the serum theophylline level.
Furthermore, theophylline has not been reported to
increase the serum level of any CK-elevating drug.
In conclusion, our results showed that treatment
with theophylline and CK-elevating drugs in combi-
nation increases the serum CK level, while their single
use does not. Furthermore, this synergistic effect is
not caused by an increase in the serum theophylline
level, which seems to indicate a pharmacodynamic
drug interaction. This synergistic effect may be
associated with adverse reactions, but further studies
are required to confirm its clinical implications.
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